New drugs, new rashes: Update on cutaneous drug reactions

Advances in Dermatology

Volumn 21, Issue , 2005, Pages 279-302

  Burgin, Susan ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 29244485190     PISSN: 08820880     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.yadr.2005.03.002     Document Type: Review

References (108)

1. Bigby M: Rates of cutaneous reactions to drugs. Arch Dermatol 137:765-770, 2001.
2. Susser W, Whitaker-Worth D, Grant-Kels J: Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 40:367-392, 1999.
3. Ross JS, Schenken DP, Pietrusko R, et al: Targeted therapies for cancer 2004. Am J Clin Pathol 122:598-609, 2004.
4. Blackledge G, Averbuch S: Gefitinib ("Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer 90:566-572, 2004.
5. Van Doorn R, Kirtschig G, Scheffer E, et al: Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 147:598-601, 2002.
6. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290:2149-2158, 2003.
7. Busam KJ, Capodieci P, Motzer R, et al: Cutaneous side-effects in cancer patients treated with antiepidermal growth factor receptor antibody C225. Br J Dermatol 144;1169-1176, 2001.
8. Hidalgo M, Siu LL, Nemunaitis J, et al: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19:3267-3279, 2001.
9. Perez-Soler R, Chachoua A, Hammond LA, et al: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22:3238-3247, 2004.
10. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004.
11. Perez-Soler R: Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncol (Huntingt) 17:23-28, 2003.
12. Herbst RS, LoRusso PM, Purdom M, et al: Dermatologic side effects associated with gefitinib therapy: Clinical experience and management. Clin Lung Cancer 4:366-369, 2003.
13. Trojan A, Jacky E, Follath F, et al: Necrolytic migratory erythema (glucagonoma)-like skin lesions induced by EGF-receptor inhibition. Swiss Med Weekly 133:22, 2003.
14. Monti M, Mancini LL, Ferrari B, et al: Complications of therapy and a diagnostic dilemma case. Case 2. Cutaneous toxicity induced by cetuximab. J Clin Oncol 21:4651-4653, 2003.
15. Boucher KW, Davidson K, Mirakhur B, et al: Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody. J Am Acad Dermatol 47:632-633, 2002.
16. Guilhot F: Indications for imatinib mesylate therapy and clinical management. Oncologist 9:271-281, 2004.
17. MacArthur G: Molecularly targeted treatment for dermatofibrosarcoma protuberans. Semin Oncol 31:30-36, 2004.
18. Cools J, DeAngelo DJ, Gotlib J, et al: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348:1201-1214, 2003.
19. Pardanani A, Tefferi A: Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood 104:1931-1939, 2004.
20. Sawyers CL, Hochhaus A, Feldman E, et al: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study. Blood 99:3530-3539, 2002.
21. Talpaz M, Silver RT, Druker BJ, et al: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 99:1928-1937, 2002.
22. Van Oosterom AT, Judson I, Verweij L, et al: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 358:1421-1423, 2001.
23. Valeyrie L, Bastuji-Garin S, Revuz J, et al: Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: A prospective study of 54 patients. J Am Acad Dermatol 48:201-206, 2003.
24. Hensley ML, Ford JM: Imatinib treatment: Issues related to safety, fertility and pregnancy. Semin Hematol 40:21-25, 2003.
25. Schwarz M, Kreuzer KA, Baskaynak G, et al: Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia. Eur J Haematol 69:254-256, 2002.
26. Brouard MC, Prins C, Mach-Pascual S, et al: Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia. Dermatology 203:57-59, 2001.
27. Konstantopoulos K, Papadogianni A, Dimopoulou M, et al: Pityriasis rosea associated with imatinib (STI571, Gleevec). Dermatology 205:172-173, 2002.
28. Lim DS, Muir J: Oral lichenoid reaction to imatinib (STI 571, Gleevec). Dermatology 205:169-171, 2002.
29. Ugurel S, Hildenbrand R, Dippel E, et al: Dose-dependent severe cutaneous reactions to imatinib. Br J Cancer 88:1157-1159, 2003.
30. Miyagawa S, Fujimoto H, Ko S, et al: Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumour. Br J Dermatol 147:406-407, 2002.
31. Raanani P, Goldman JM, Ben-Bassat I: Challenges in oncology. Case 3. Depigmentation in chronic myeloid leukemic patient treated with STI-571. J Clin Oncol 20:869-870, 2002.
32. Tsao A, Kantarjian H, Cortes J, et al: Imatinib mesylate causes hypopigmentation in the skin. Cancer 98:2483-2487, 2003.
33. Etienne G, Cony-Makhoul P, Mahon F-X: Imatinib mesylate and gray hair. N Engl J Med 347:446, 2002.
34. Abushullaih S, Saad E, Hoff PM: Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: A single-institution experience. Cancer Invest 20:3-10, 2002.
35. Lewis K, Lewis M, Boston-Robinson L, et al: Inflammation of actinic keratoses during capecitabine therapy. Arch Dermatol 140:367-368, 2004.
36. Ghetti E, Piraccini BM, Tosti A: Onycholysis and subungual haemorrhages secondary to systemic chemotherapy (paclitaxel). J Eur Acad Dermatol Venereol 17:459-460, 2003.
37. Chu CY, Yang CH, Yang CY, et al: Fixed erythrodysaesthesia plaque due to intravenous injection of docetaxel. Br J Dermatol 142:808-811, 2000.
38. Chen M, Crowson AN, Woofter M, et al: Docetaxel (taxotere) induced subacute cutaneous lupus erythematosus: Report of 4 cases. J Rheumatol 31:818-820, 2004.
39. Khanna D, McMahon M, Furst DE: Safety of tumor necrosis factor-alpha antagonists. Drug Saf 27:307-324, 2004.
40. Etanercept package insert: 7/6/04.
41. Infliximab package insert: 7/6/04.
42. Adalimumab package insert: 7/6/04.
43. Vermeire S, Noman M, Van Assche G, et al: Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: A prospective cohort study. Gastroenterology 125:32-39, 2003.
44. Furst DE, Schiff MH, Fleischmann RM, et al: Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: Results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 30:2563-2571, 2003.
45. Mohan AK, Edwards ET, Cote TR, et al: Drug-induced systemic lupus erythematosus and TNF-alpha blockers. Lancet 360:646, 2002.
46. Mohan N, Edwards ET, Cupps TR, et al: Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol 31:1955-1958, 2004.
47. Galaria NA, Werth VP, Schumacher HR: Leukocytoclastic vasculitis due to etanercept. J Rheumatol 27:2041-2044, 2000.
48. McCain ME, Quinet RJ, Davis WE: Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology 41:116-117, 2002.
49. Zeltser R, Valle L, Tanck C, et al: Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: A recombinant tumor necrosis factor α receptor: Fc fusion protein. Arch Dermatol 137:893-899, 2001.
50. Weinblatt ME, Keystone EC, Furst DE, et al: Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 48:35-45, 2003.
51. Vergara G, Silvestre JF, Betlloch I, et al: Cutaneous drug eruption to infliximab: Report of 4 cases with an interface dermatitis pattern. Arch Dermatol 138:1258-1259, 2002.
52. Devos SA, van den Bosche N, de Vos M, et al: Adverse skin reactions to anti-TNFα monoclonal antibody therapy. Dermatology 206:388-390, 2003.
53. Beuthien W, Mellinghoff HU, von Kempis J: Skin reaction to adalimumab. Arthritis Rheum 50:1690-1692, 2004.
54. Smith KJ, Skelton HG: Rapid onset of cutaneous squamous cell carcinomas in patients with rheumatoid arthritis after starting tumor necrosis factor α receptor IgG-Fc fusion complex therapy. J Am Acad Dermatol 45:953-956, 2001.
55. Esser AC, Abril A, Fayne S, et al: Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab. J Am Acad Dermatol 50:575-577, 2004.
56. Bozkurt B: Cardiovascular toxicity with highly active antiretroviral therapy: Review of clinical studies. Cardiovasc Toxicol 4:243-260, 2004.
57. Garg A: Acquired and inherited lipodystrophies. N Engl J Med 350:1220-1234, 2004.
58. Carr A, Samaras K, Thorisdottir A, et al: Daignosis, prediction and natural course of HIV-1-protease-inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus: A cohort study. Lancet 353:2093-2099, 1999.
59. Ward HA, Russo GG, Shrum J: Cutaneous manifestations of antiretroviral therapy. J Am Acad Dermatol 46:284-293, 2002.
60. Warren KJ, Boxwell DE, Kim NY, et al: Nevirapine-associated Stevens-Johnson syndrome. Lancet 351:567, 1998.
61. Pollard RB, Robinson P, Dransfield K: Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther 20:1071-1092, 1998.
62. Anton P, Soriano V, Jimenez-Nacher I, et al: Incidence of rash and discontinuation of nevirapine using two different escalating initial doses. AIDS 13:524-525, 1999.
63. Montaner JS, Cahn P, Zala C, et al: Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. J Acquir Immune Defic Syndr 33:41-46, 2003.
64. Bersoff-Matcha SV, Miller WC, Aberg JA, et al: Sex differences in nevirapine rash. Clin Infect Dis 32:124-129, 2001.
65. Bigby M, Jick S, Jick H, et al: Drug-induced cutaneous reactions: A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA 256:3358-3363, 1986.
66. Naldi L, Conforti A, Venegoni M, et al: Cutaneous reactions to drugs: An analysis of spontaneous reports in four Italian regions. Br J Clin Pharmacol 48:839-846, 1999.
67. Claudio GA, Martin AF, de Dios Perrino S, et al: DRESS syndrome associated with nevirapine therapy. Arch Intern Med 161:2501-2502, 2001.
68. Phillips EJ, Sullivan JP, Knowles SR, et al: Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS 16:2223-2225, 2002.
69. Mallal S, Nolan D, Witt C, et al: Association between the presence of HLA-B*5701, HLA-DR7 and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359:727-732, 2002.
70. Hetherington S, Hughes AR, Mosteller M, et al: Genetic variations in the HLA-B region and abacavir hypersensitivity. Lancet 359:1121-1122, 2002.
71. Powderly W: Metabolic complications associated with HIV infection and antiretroviral therapy. AIDS Pat Care STDs 18:431-435, 2004.
72. Kilby JM, Eron JJ: Mechanisms of disease: Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med 348:2228-2238, 2003.
73. Fung HB, Guo Y: Enfuvirtide: A fusion inhibitor for the treatment of HIV infection. Clin Ther 26:352-378, 2004.
74. Ball A, Kinchelow T: Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. J Am Acad Dermatol 49:826-831, 2003.
75. Maggi P, Ladisa N, Cinori E, et al: Cutaneous injection site reactions to long-term therapy with enfuvirtide. J Antimicrob Chemother 53:678-681, 2004.
76. Knowles SR, Shapiro LE, Shear NH: Reactive metabolites and adverse drug reactions. Clin Rev All Immunol 24:229-238, 2003.
77. Lieberman DZ, Goodwin FK: Separate and concomitant use of lamotrigine, lithium, and divalproex in bipolar disorders. Curr Psychiatry Rep 6:459-465, 2004.
78. Simpson DM, McArthur JC, Olney R, et al: Lamotrigine for HIV-associated painful sensory neuropathies: A placebo-controlled trial. Neurology 60:1508-1514, 2003.
79. Brown TS, Appel JE, Kasteler J, et al: Hypersensitivity reaction in a child due to lamotrigine. Pediatr Derm 16:46-49, 1999.
80. Hsiao CJ, Lee JY, Wong TW, et al: Extensive fixed drug eruption due to lamotrigine. Br J Dermatol 144:1289-1291, 2001.
81. Schlienger RG, Knowles SR, Shear NH: Lamotrigine-associated anticonvulsant hypersensitivity syndrome. Neurology 51:1172-1175, 1998.
82. Lamotrigine package insert: 1/19/05.
83. Guberman AH, Besag FM, Brodie MJ, et al: Lamotrigine-associated rash: Risk/benefit considerations in adults and children. Epilepsia 40:985-991, 1999.
84. Wong IC, Mawer GE, Sander JW: Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother 33:1037-1042, 1999.
85. The Danish Oxcarbazepine Study Group: Oxcarbazepine in patients hypersensitive to carbamazepine. Acta Neurol Scand 70:223-233, 1984.
86. Bosdure E, Cano A, Roquelaure B, et al: Oxcarbazepine and DRESS syndrome: A paediatric cause of acute liver failure. Arch Pediatr 11:1073-1077, 2004.
87. Asconape JJ: Some common issues in the use of antiepileptic drugs. Semin Neurol 22:27-40, 2002.
88. Hunziker T, Kunzi UP, Braunschweig S, et al: Comprehensive hospital drug monitoring (CHDM): Adverse skin reactions, a 20-year survey. Allergy 52:388-393, 1997.
89. Oberholzer B, Hoigne R, Hartmann K, et al: Incidence of drug side effects by symptoms and syndromes. From the experiences of the Comprehensive Hospital Drug Monitoring and the Swiss Drug Side Effect Center - as an example: Allergic and pseudo-allergic reactions with mild analgesics and NSAID. Ther Umsch 50:13-19, 1993.
90. Goeschke B, Braathen LR: Acute generalized exanthematic pustulosis: A case and an overview of side effects affecting the skin caused by celecoxib and other COX-2 inhibitors reported so far. Dermatology 209:53-56, 2004.
91. Schneider F, Meziani F, Charthier C, et al: Fatal allergic vasculitis associated with celecoxib. Lancet 359:852-853, 2002.
92. Knowles SR, Phillips EJ, Wong G, et al: Serious dermatologic reaction associated with valdecoxib: Report of two cases. J Am Acad Dermatol 2004:51:1028-1029.
93. Carder KR, Weston WL: Rofecoxib-induced instant aquagenic wrinkling of the palms. Pediatr Derm 19:353-355, 2002.
94. Swan L, Merck Sharp & Dohme (Australia) Pty Ltd. (1 October 2004): Urgent Medicine Recall VIOXX® (rofecoxib) - Merck Announces Voluntary Worldwide Withdrawal of VIOXX. Press release.
95. Juni P, Nartey L, Reichenbach S, et al: Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis. Lancet 364:2021-2029, 2004.
96. http://www.fda.gov/cder/drug/advisory/nsaids.htm. Downloaded 1/16/05.
97. FitzGerald GA: Coxibs and cardiovascular disease. N Engl J Med 351:1709-1711, 2004.
98. Crofford LJ, Oates JC, McCune WJ, et al: Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases. Arthritis Rheum 43:1891-1896, 2000.
99. Shapiro L, Knowles S, Weber E, et al: Safety of celecoxib in individuals allergic to sulphonamide. Drug Saf 26:187-195, 2003.
100. Glasser DL, Burroughs SH: Valdecoxib-induced toxic epidermal necrolysis in a patient allergic to sulfa drugs. Pharmacother 2003:23:551-553, 2003.
101. Kaur C, Sarkar R, Kanwar AJ: Fixed drug eruption to rofecoxib with cross-reactivity to sulphonamides. Dermatology 203:351, 2001.
102. Clopidogrel package insert: 1/22/05.
103. Cannavo SP, Borgia F, Guarneri M, et al: Acute generalized exanthematous pustulosis following use of ticlopidine. Br J Dermatol 142:577, 2000.
104. CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329-1339, 1996.
105. Wolf I, Mouallem M, Rath S, et al: Clopidogrel-induced systemic inflammatory response syndrome. Mayo Clin Proc 78:618-620, 2003.
106. Gurbuz AT, Elliott WG, Zia AA: Heparin-induced thrombocytopenia in the cardiovascular patient: Diagnostic and treatment guidelines. Eur J Cardiothorac Surg 27:138-149, 2005.
107. Handschin AE, Trentz O, Kock HJ, et al: Low molecular weight heparin-induced skin necrosis - a systematic review. Langenbecks Arch Surg November 27, 2004. Online publication ahead of print.
108. Gurbuz AT, Elliott WG, Zia AA: Heparin-induced thrombocytopenia in the cardiovascular patient: Diagnostic and treatment guidelines. Eur J Cardiothorac Surg 27:138-149, 2005.